2000年至2011年西澳大利亚地区脑膜炎奈瑟菌porA、fetA和fHbp基因分布情况
Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011.
作者信息
Boan Peter, Metasan Norhaliza, Tempone Simone, Harnett Gerry, Speers David J, Keil Anthony D
机构信息
Department of Microbiology, PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children, Roberts Road, Subiaco 6008, Australia.
出版信息
BMC Infect Dis. 2014 Dec 12;14:686. doi: 10.1186/s12879-014-0686-x.
Abstract
BACKGROUND
PorA, fetA and fHbp are three antigen encoding genes useful for meningococcal typing and FHbp is an important component of meningococcal B vaccines.
METHODS
We performed sequence analysis of meningococcal porA, fetA and fHbp genes on 128 isolates from Western Australia, relating results to age, gender, race and geographic region.
RESULTS
We found predominantly PorA subtypes P1.22,14-16 (n = 23) and P1.7-2,4 (n = 19); FetA subtypes F1-5 (n = 41), F3-6 (n = 11), F5-1 (n = 10), F5-2 (n = 9), F5-5 (n = 8), F3-3 (n = 8); and FHbp variant groups 1 (n = 65) and 2 (n = 44). PorA P1.22,14-16 and FHbp variant group 2 were associated with younger age and aboriginality.
CONCLUSIONS
FHbp modular groups of the bivalent recombinant FHbp vaccine and the multicomponent 4CMenB vaccine make up 8.3% and 47.7% respectively of the examined serogroup B isolates from 2000-2011, however to estimate vaccine efficacy requires an account of all vaccine antigens and their levels of expression.
摘要
背景
PorA、fetA和fHbp是三种用于脑膜炎球菌分型的抗原编码基因，且fHbp是B群脑膜炎球菌疫苗的重要组成部分。
方法
我们对来自西澳大利亚的128株分离株进行了脑膜炎球菌porA、fetA和fHbp基因的序列分析，并将结果与年龄、性别、种族和地理区域相关联。
结果
我们主要发现了PorA亚型P1.22,14 - 16（n = 23）和P1.7 - 2,4（n = 19）；FetA亚型F1 - 5（n = 41）、F3 - 6（n = 11）、F5 - 1（n = 10）、F5 - 2（n = 9）、F5 - 5（n = 8）、F3 - 3（n = 8）；以及fHbp变异组1（n = 65）和2（n = 44）。PorA P1.22,14 - 16和fHbp变异组2与较年轻的年龄和原住民身份相关。
结论
二价重组fHbp疫苗和多组分4CMenB疫苗的fHbp模块化组分别占2000 - 2011年检测的B群分离株的8.3%和47.7%，然而要评估疫苗效力需要考虑所有疫苗抗原及其表达水平。
相似文献
1
Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011.2000年至2011年西澳大利亚地区脑膜炎奈瑟菌porA、fetA和fHbp基因分布情况
BMC Infect Dis. 2014 Dec 12;14:686. doi: 10.1186/s12879-014-0686-x.
2
Molecular characterization of a collection of Neisseria meningitidis isolates from Croatia, June 2009 to January 2014.2009年6月至2014年1月从克罗地亚收集的脑膜炎奈瑟菌分离株的分子特征
J Med Microbiol. 2016 Sep;65(9):1013-1019. doi: 10.1099/jmm.0.000320. Epub 2016 Jul 22.
3
Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Isolated from 2009 to 2013 in the Republic of Ireland.爱尔兰共和国 2009 至 2013 年分离的侵袭性 B 群血清型 4CMenB 疫苗的潜在覆盖范围。
mSphere. 2018 Aug 22;3(4):e00196-18. doi: 10.1128/mSphere.00196-18.
4
Factor H binding protein (FHbp): An evaluation of genotypic diversity across serogroups.因子 H 结合蛋白（FHbp）：对各血清群的基因多样性评估。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2409502. doi: 10.1080/21645515.2024.2409502. Epub 2024 Oct 10.
5
Molecular characterization of invasive isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage.2009-2019 年在立陶宛采集的侵袭性分离株的分子特征及 B 群脑膜炎球菌疫苗 4CMenB 和 MenB-Fhbp 覆盖率的评估。
Front Cell Infect Microbiol. 2023 Feb 15;13:1136211. doi: 10.3389/fcimb.2023.1136211. eCollection 2023.
6
A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.多国脑膜炎奈瑟菌 B 群因子 H 结合蛋白评估及其对不同年龄组疫苗覆盖率的影响。
Pediatr Infect Dis J. 2013 Oct;32(10):1096-101. doi: 10.1097/INF.0b013e31829aa63b.
7
Genetic and antigenic characterization of Canadian invasive Neisseria meningitidis serogroup C (MenC) case isolates in the post-MenC conjugate vaccine era, 2009-2013.2009 - 2013年加拿大侵袭性脑膜炎奈瑟菌C群（MenC）病例分离株在MenC结合疫苗时代的基因和抗原特征分析
J Med Microbiol. 2015 Feb;64(Pt 2):174-9. doi: 10.1099/jmm.0.000006-0.
8
Determination of serotyping antigens, clonal analysis and genetic characterization of the 4CMenB vaccine antigen genes in invasive Neisseria meningitidis from Western Canada, 2009 to 2013.2009 年至 2013 年，加拿大西部侵袭性脑膜炎奈瑟菌中 4CMenB 疫苗抗原基因的血清分型抗原、克隆分析和遗传特征的测定。
J Med Microbiol. 2014 Nov;63(Pt 11):1490-1499. doi: 10.1099/jmm.0.079921-0. Epub 2014 Aug 27.
9
Molecular characterization of Neisseria meningitidis isolates recovered from 11-19-year-old meningococcal carriers in Salvador, Brazil.从巴西萨尔瓦多11至19岁脑膜炎球菌携带者中分离出的脑膜炎奈瑟菌菌株的分子特征分析。
PLoS One. 2017 Sep 20;12(9):e0185038. doi: 10.1371/journal.pone.0185038. eCollection 2017.
10
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.2008年1月在英格兰和威尔士收集的B群脑膜炎球菌病例分离株中fHbp、nhba（gna2132）、nadA、porA的特征及序列类型，以及一种研究性B群脑膜炎球菌疫苗的潜在覆盖率
Clin Vaccine Immunol. 2010 Jun;17(6):919-29. doi: 10.1128/CVI.00027-10. Epub 2010 Apr 7.
引用本文的文献
1
Genomic surveillance of invasive Neisseria meningitidis isolates circulating in Paraguay, 2009-2021.2009 - 2021年巴拉圭侵袭性脑膜炎奈瑟菌分离株的基因组监测
Int Microbiol. 2025 Jun 17. doi: 10.1007/s10123-025-00685-0.
2
Genetic and Antigenic Diversity of Serogroup B Strains in Vietnam.越南B群菌株的遗传和抗原多样性
Pathogens. 2025 May 15;14(5):487. doi: 10.3390/pathogens14050487.
3
Microevolution and Its Impact on Hypervirulence, Antimicrobial Resistance, and Vaccine Escape in .微进化及其对……中高毒力、抗菌药物耐药性和疫苗逃逸的影响
Microorganisms. 2023 Dec 18;11(12):3005. doi: 10.3390/microorganisms11123005.
4
The Epidemiology of Meningococcal Disease and Carriage, Genotypic Characteristics and Antibiotic Resistance of Isolates in Zhejiang Province, China, 2011-2021.2011 - 2021年中国浙江省脑膜炎球菌病的流行病学、携带情况、分离株的基因型特征及抗生素耐药性
Front Microbiol. 2022 Jan 24;12:801196. doi: 10.3389/fmicb.2021.801196. eCollection 2021.
5
Differences in the population structure of Neisseria meningitidis in two Australian states: Victoria and Western Australia.澳大利亚两个州（维多利亚州和西澳大利亚州）脑膜炎奈瑟菌种群结构的差异。
PLoS One. 2017 Oct 24;12(10):e0186839. doi: 10.1371/journal.pone.0186839. eCollection 2017.
6
Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.西澳大利亚州15年间与脑膜炎奈瑟菌遗传谱系相关的BEXSERO®抗原序列类型的时间变化
PLoS One. 2016 Jun 29;11(6):e0158315. doi: 10.1371/journal.pone.0158315. eCollection 2016.
本文引用的文献
1
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.预测脑膜炎球菌多组份疫苗（4CMenB）在欧洲的菌株覆盖率：定性和定量评估。
Lancet Infect Dis. 2013 May;13(5):416-25. doi: 10.1016/S1473-3099(13)70006-9. Epub 2013 Feb 13.
2
Annual report of the Australian Meningococcal Surveillance Programme, 2011.《2011年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2012 Sep 30;36(3):E251-62.
3
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.18-36 月龄健康婴幼儿接种脑膜炎 B 型两价 rLP2086 疫苗的安全性和免疫原性：一项 1 期随机对照临床试验。
Pediatr Infect Dis J. 2012 Oct;31(10):1061-8. doi: 10.1097/INF.0b013e31826327e4.
4
Australian Meningococcal Surveillance Programme annual report, 2010.《2010年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2011 Sep;35(3):217-28.
5
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.健康青少年中脑膜炎奈瑟菌 B 型二价重组脂蛋白 2086 疫苗的安全性、免疫原性和耐受性：一项随机、单盲、安慰剂对照、2 期临床试验。
Lancet Infect Dis. 2012 Aug;12(8):597-607. doi: 10.1016/S1473-3099(12)70087-7. Epub 2012 May 7.
6
Vaccines targeting serogroup B meningococci.针对B群脑膜炎球菌的疫苗。
Lancet Infect Dis. 2012 Aug;12(8):578-9. doi: 10.1016/S1473-3099(12)70093-2. Epub 2012 May 7.
7
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.根据不同免疫计划，与常规婴儿疫苗联合或不联合使用时重组 B 群脑膜炎球菌疫苗的免疫原性和耐受性：一项随机对照试验。
JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85.
8
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.在智利健康青少年中，一种包含多种脑膜炎奈瑟菌 B 群（4CMenB）组份的疫苗的免疫原性和耐受性：一项 2b/3 期、随机、观察者盲、安慰剂对照研究。
Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18.
9
Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies.脑膜炎奈瑟菌因子 H（fH）结合蛋白多种亚型的特性鉴定，包括与 fH 的结合能力、介导血清抗性的能力以及诱导杀菌抗体的能力。
Infect Immun. 2011 Feb;79(2):970-81. doi: 10.1128/IAI.00891-10. Epub 2010 Dec 13.
10
Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa.除 B 群之外的因子 H 结合蛋白分布：南非侵袭性脑膜炎奈瑟菌五个血清群之间的差异。
Vaccine. 2011 Mar 3;29(11):2187-92. doi: 10.1016/j.vaccine.2010.11.072. Epub 2010 Dec 7.
Zotero 插件